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EFFECT OF INTERLEUKIN 1 AND 
LEUKAEMIA INHIBITORY FACTOR 
ON CHONDROCYTE METABOLISM IN 
ARTICULAR CARTILAGE FROM NORMAL 
AND INTERLEUKIN-6-DEFICIENT MICE: 
ROLE OF NITRIC OXIDE AND IL-6 IN THE 
SUPPRESSION OF PROTEOGLYCAN SYNTHESIS
Fons A. J. Van de Loo, Onno J. Arntz, Wim B. Van den Berg
We studied the role of IL-6 and nitric oxide (NO) in IL-1 and leukaemia inhibitory factor (LIF) 
induced suppression of proteoglycan synthesis. Cartilage explants of patellae and femoral heads 
were incubated with IL-1 or LIF. Conditioned media were analysed for IL-6 activity (B9-assay) 
and NO content (Griess). Proteoglycan synthesis was assessed using pSJsulfate incorporation. 
IL-1 dose dependency induced IL-6 synthesis and neutralizing IL-6 with antibodies did not 
reduce proteoglycan synthesis suppression, neither in expiants nor in isolated chondrocytes. IL-6 
independence was confirmed using cartilage from IL-6 deficient mice. IL-1 significantly increased 
NO release in normal and IL-6 deficient chondrocytes and addition of the NO synthase inhibitor, 
N^-monomethyl-L-arginine markedly alleviated proteoglycan synthesis suppression. LIF also 
induced proteoglycan synthesis suppression in cartilage from normal and IL-6 deficient mice, 
but the suppression was neither accompanied by nor dependent on NO release. Furthermore, 
proteoglycan synthesis suppression during experimental arthritis was similar in both normal and 
IL-6 deficient mice. We concluded that IL-6 is not a necessary cofactor in IL-1 and LIF induced 
suppression of proteoglycan synthesis. Furthermore, only the IL-1 induced suppression was 
mediated by NO, suggesting that inhibition of proteoglycan synthesis may occur through 
different pathways.
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Cytokines are im portant mediators in the pa tho ­
genesis o f  rheum atoid arthritis (R A )1'" and are 
produced in the inflamed jo in t.14 It has been claimed 
that T N F -a  is driving most of the IL-1 production 
in the inflamed synovia of RA patients5 suggesting a 
hierarchy in the dynamic interaction of cytokines. The
cascade of T N F IL-1 L IF  —> IL-6 was
to be involved in the pathogenesis o f RA.6
T N F -a  and IL-1 share many of their
activities,7 and the therapeutic intervention of RA is 
recently directed towards antagonizing and modifying
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:k -ou i m ice/n itr ic  oxide/
the action of these proximal cytokines,8 Approaches 
with anti-TNF antibody and IL-1 receptor antagonist 
( I L - l r a )
!nl> 14arthritis
of anti- 
latter
in animal 
and recent clinical trials
treatment in RA patients., is 17
#c prevents cartilage desti
has yet to be determined and a better understanding of 
mediators downstream the cytokine cascade may 
provide more optimal therapeutic targets.
Carelli! analysis of the anism of cartilage
destruction in murine arthritis showed a pivotal
r of IL-1 in chondrocyte
inhibition.M,IK Moreover, anti-IL-1 treatment not only 
abolished this suppression but also reduced the net
(overall) depletion of cartilage matrix.’4,1'1'’1 An essential 
eostimulalory role for IL-6 was claimed in the IL-1 
induced suppression of proteoglycan synthesis, using 
expiants of human articular cartilage.'1’'’ Although 
this dependency is not yet confirmed by other groups, 
it is generally accepted that 1L-I is a potent inducer 
o f IL-6 production in cells o f articular tissues, including 
synovial fibroblasts and chondrocytes.’’ 
ingly, a cytokine belonging to a family of IL-6-retaled 
proteins,
ìrest-
'aemia inhibitory factor (LIF), is also
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capi O f i chondrocyte proteoglycan proteoglycan synthesis were IL-6 independent, in vitro
synthesis.26 LIF is a single-chain, polypeptide cytokine and in vivo. Furthermore, we confirmed the mediating 
of approximately 20 kDa inducible in synoviocytes and role of NO in IL -1 induced suppression, but clearly
articular chondrocytes by IL-l, - On chondrocytes, 
LIF was able to induce IL-1 and IL-6 syn thesis.27,2R 
However, LIF induced suppression of proteoglycan 
synthesis was IL-1 independent.25
Recent studies suggested an essential role of 
nitric-oxide (NO) in IL-1-induced suppression of 
chondrocyte proteoglycan synthesis.29,30 Suppression 
could be prevented by t-arginine analogues, which are
potent inhibitors of NO , , , , 0 Whether NO
is also involved in the action of LIF has yet to be
In the present study we examined the role of IL-6
:ind NO in IL-1 and LIF induced of
chondrocyte proteoglycan synthesis, both in vitro and 
in vivo. Since anti-IL-6 antibodies may have difficulty 
in penetrating intact cartilage, in vitro studies were 
performed with murine articular cartilage explants as 
well as isolated chondrocytes. Moreover, comparable 
experiments were done in IL-6-deficient mice. It was 
shown that both IL-1 and LIF action on chondrocyte
showed that the LIF effect was NO independent. 
Our data suggest that IL-6 is not a feasible down-
srapy, tostream target to fine tune IL-1 
prevent cartilage damage. Furthermore, the strategy of 
NO blocking will affect IL-1 action, but not 
of LIF.
RESULTS
Effect o f IGF-1 and IL-t on chondrocyte
In order to maintain in vivo n
proteoglycan synthesis during culture, patellae werte
incubated in the presence of 0.25 j-ig/ml insulin-like 
growth fac
IL-6 f / I
ocytes m patellae from 
rnd IL-60/" mice showed an identical IGF-1
response in vitro (Fig. 1). For this, cartilage was
incubated in presence of 0.25 pg/ml IGF-1 in
the next experiments.
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Figure I. ÏL-1-intluced suppression of proteoglycan synthesis in (A) IL-6i/(  and IL-60/B mice.
Patellae were incubated for 24 h in culture medium (n -■ id by a 3 h pulse with (“S|sulf';ite (20 }i('i tul), 
incorporation is a measure of ehondrocylc proteoglycan synthesis. The effect ol'lniman recombinani ICH-1 (0.25 Mg mil «nil 
murine recombinant IL-la (l()ng/ml) on proteoglycan synthesis was assessed. IL-6 concentrations of conditioned media of 
patellae from the IL-6-deIicient mice (C57BI/6xl29Sv, IL-6«-") were below the detection limit of' the fW ¡issuv (• f),2pgml). 
Statistical significance was tested by using the student’s r-test. */‘ < 0.05.
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TABLE I. Effect of exogenous IL-1 on chondrocyte synthesis of proteoglycans and IL-6,
Patellar cartilage expiants* Femoral head cartilage explantsf
IL-1J [M]Sulfate§ IL-611 [HS]sulfate IL-6
dose incorporation concentration incorporation concentration
Mice (ng/ml) (epm ±  SD) (ng/ml) (epm + SD) (ng/ml)
C57B1/6 (IL-6+/ + ) 0 2365 ±  259 149 9758 ± 1877 0.37
0.1 1552 ±  131** 199 7650 ±  2240** 2.48
1.0 1157 ±  239** 299 5871 + 642** 4.98
*Patallae (n = 6) with a minimal amount of adjacent soft tissue. 
tFemoral head cartilage expiants (// — 6).
JMedium changed after 24 h (200 j.il of RPM1 -b 0.25 j-ig/ml IGF-1 
¡{Proteoglycan synthesis (mean value ± SD) us measured by ['5S]sulfate 
IITolal IL-6 produced during the 48-h incubation period as measur
per explant).
2incorporation in the last 3 h of the 48~h incubation period 
with the B9-assay as described in Materials and Methods
Value of pooled samples.
Control group and IL-1-treated group were tested using the Student's /-test, values statistically significant: ** /'<0 .05 .
Role o f endogenous IL-6 in the IL-l-induced 
suppression o f proteoglycan synthesis
Murine recombinant IL - la  induced a dose-related 
inhibition of chondrocyte proteoglycan synthesis in 
patellae and femoral head cartilage explants o f mice 
(Table 1). In the culture media, IL-6 levels increased 
using higher IL-1 concentrations. Next, we studied the 
role of endogenous IL-6 by neutralizing IL-6 activity 
with anti-IL-6 antibodies during culture. For this, 
explants of femoral head cartilage were used as the IL-6 
levels in the culture media was less than 2%  of 
the values found in cultures o f patellae. Addition of 
10 jug/ml rat-anti mouse IL-6 monoclonal antibodies 
completely neutralized IL-6 activity during culture 
without changing normal proteoglycan synthesis rate 
and the IL-1 suppression (Table 2). Since the size of 
antibodies (150 kDa) may hamper 
the cartilage matrix, IL-6 neutralization 
were also performed on isolated chondrocytes. IL-1 
significantly suppressed proteoglycan 
isolated murine chondrocytes either in 
( — 41 ±  7%, mean of four experiments) or presence of
i n t o
anti-IL-6 monoclonal antibodies ( — 47 H- 9%, mean of 
four experiments) (Table 2). This argues a
major role of endogenous IL-6 in the IL-l-induced 
suppression of proteoglycan synthesis in IL-61 ' 1 mice. 
Murine recombinant IL -la  (10ng/ml) induced a 
pronounced suppression of proteoglycan synthesis 
in patellae of IL-6l,/" mice, which was at least as high
littermates (Fig. 1). Thisas that found in IL-6 
suggest that IL-6 was not necessary for a full-blown 
IL-1 effect on proteoglycan synthesis.
Effect o f exogenous IL-6 on normal and
IL-1 -affected proteoglycan—and NO synthesis in
IL-6 deficient mice and their normal littermates
IL-1 evoked increasing levels o f nitrite, a stable 
product of NO, in the culture medium of cartilage 
ants obtained from either normal or IL-6 deficient
mice (Table 3), This showed that endogenous IL-6 was 
not an essential intermediate in the IL-l-induced NO 
release. Incubating patellae or femoral head cartilage 
explants with murine recombinant IL-6 did not
suppress proteoglycan nor
FABLE 2. Effect of IL-6 neutralization on IL-1 -induced suppression of proteoglycan synthesis.
Femoral head curtilage expiants* Femoral head chonclrocylesf
M ice
Culture mediumf
N i l  Ï  A
I L - 1 A IL-6 Ab
["S]sullate§
incorpora tion
(epm +
IL-61
concentration incorporation
«.Ji'/i
11,-6
concentration
C57B1/6 (IL-6‘ ’ ) ir . • * *• • 8588 i- 816 412 1032 ± 184 480
h 9220 f 1104 <  I 1160 + 128 < 1
a  j i M a . 6468 + 396 2400 700 ± 168 960
+ + 5848 1- 892 < 1 608 ±  100 < 1
’’Femoral head cartihigc explants (/; ~ 6), 1 explants per 200j.il medium supplemented with 0.25 ng/ml IGF-1. Medium changed after 24 h, 
and the total incubation period was 48 h.
flsolated femoral head cartilage chondrocytes, 44 000 cells in 200 jil medium supplemented with 5% FCS, per Hal-bottom well of a microlitre 
plate.
{The IL-la concentrations were, respectively, 10ng/ml and I ng/ml in the explant and chondrocyte cultures. The rut-unti-IL-6 monoclonal 
antibody concentrations was 10 jtg/ml in both expiant and chondrocyte culture, enough to block 70 ng of IL-6 in the IW-assay. 
¿¡Proteoglycan synthesis (mean value ±  SD) as measured by [HS]sullatc (20 jiCi/ml) uptake during the last 3 h of incubation, in chondrocyte 
culture, values were CPC-precipitated [HS]sullate incorporated proteoglycans-
IITolal IL-6 produced during the 48-h incubation period as measured with the B9-assay as decribed in Materials and Methods, Value of
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TABLE 3. Effect of exogeiuMs.t SS.-6 uv. •■■it Sie lit'sis of proteoglycans and NO
i'nlcliar cariibiye expiants Femoral head cartilage expiants!
.  , v  '  f i  V *
Mice
Culture
medium"
I ’ |Siiliat«..-:j: 
incorporation
(epm ± SO)
NitriteS
concentration
(uM)
[’■'SJsulftile 
incorporation 
(epm ±  SD)
Nitrite
concentration
(uM)
C57B1/6 (IL-6 ' ■)
IL-1 
IL-6 
IL-1 +  IL-6
C57B1/6X129SV (IL-6"")
IL-1 
IL-6 
IL-1 ~t” IL-6
1753 ±  14« 
«32 ±  301 
1649 ±  74 
759 ±  22 
1811 ± 4 5 7  
759 ±  94 
1555 ±  141 
694 ±  82
16.4 ± 4.6
51.9 ±  16.5
9.5 ±  2.2
35.4 ±  2.3 
7.8 ±  2.0
50.2 ±  4.7
8.5 ±  1.9
27.9 ±  3.6**
9836 ± 1422 
5436 ± 874 
8335 ±  1413 
4899 ±  985 
9262 ±  891 
5839 ±  1302 
10133 ±  2546 
5566 ±  1982
9.5 ±  2.2 
28.1 ±  3.0
3.3 ±  2.9
22.4 ±  3.4**
1.4 ±  2.0 
29.1 ±  2.2
4.8 ±  2.9
20.5 ±  6.5**
♦Femoral head cartilage explains and patellae were incubated in RPMI supplemented with 0.25 Mg/ml IGF-1, I specimen per 200 \x\ medium. 
Medium was changed after 24 h. and the tola! incubation period was 48 h.
tThe IL-la concentrations were tOng/ml and 0.1 ng/ml in patellae and femoral head explants, respectively. The IL-6 concentration used was 
100 ng/ml in cultures of patellae and femoral head explants,
fProleoglyean synthesis (mean value ±  SD) as measured by l ,sS]suliate (20 j-iC'i/ml) uptake during the last 3 1) of incubation.
§NO was measured in pooled samples of both 24 h-ineubution periods tusing Griess reagents and NO* as standard.
IL-6 significantly reduced IL-1 induced nitrite levels as tested using the Wiicoxon rank sum test, **ƒ*< 0.05. A dose of 10 ng/ml IL-6 had 
no efleel on the nitrite levels (not shown).
induced NO release (Table 3). Furthermore, exogenous 
IL-6, upto 100 ng/ml, failed to modulate IL-1 induced 
suppression of proteoglycan synthesis, although the 
highest IL-6 dose significantly reduced IL-l-induced 
NO release (Table 3).
Effect of LIF on chondrocyte proteoglycan 
synthesis
High amounts of murine recombinant LIF 
(100 ng/ml) were able to decrease chondrocyte proteo-
glycan synthesis significantly for —28.0 ±  7.6% (mean 
of five experiments) in cultures of patellae (Table 4) 
and —26.3 ±  1.5% (mean of three experiments) in 
femoral head cartilage explants of IL-6+/1 mice (not 
shown). IL-6 played no role in the LIF induced
suppression of proteoglycan synthesis which was at 
least as high in explants from IL-60/0 mice (Table 4). 
However compared to IL-1, the extent of proteoglycan 
synthesis inhibition induced by LIF was considerably 
smaller (Table 4). Moreover, IL-1 induced nitric-oxide 
production, whereas the nitrite levels in the culture 
media of cartilage stimulated with LIF did not exceed 
the spontaneously produced nitrite levels (Table 4). 
This suggests that NO did not mediate the LIF-induced 
suppression of proteoglycan synthesis.
Role of NO in IL-1-, and LIF-induced 
suppression of proteoglycan synthesis
We further examined the role of NO by using 
the inhibitor of the NO-synthase, Nu-monomethyl
TABLE 4. Comparison between IL-1- and LIF-induced inhibition of  
proteoglycan synthesis.
Mice
Culture
medium
Patellar cartilage expiants*
. . s  »  » H ,  V  .  -  *  _  . . .  .  . . .  •-n ,  .  .  .  ♦  *  •  . . .  «  ,  ,  .  .  A. *
PSJsulfatei Nilritcf
incorporation concentration 
(epm ±  SD) (uM)
C57BI/6 (IL-61 ; 1 ) 1582 ±  304 21.9 ± 6.8
LIF 1208 ±  95** 18.6 ± 6.8
IL-1 433 ±51** 93.4 ±  12.9**
C57Bl/6xl29Sv (IL-61’") .  .  . 1777 ± 194 23.1 ± 6.5
LIF 1184 ±91** 27.3 ± 8.1
IL-1 558 ±  126** 119.1 + 18.3**
C57Bl/6xl29Sv (IL-61 y • ) M W  »  \ 1703 ±  173 25.2 ± 6.1
LIF 1169 ±  92** 21.9 +  3.0
IL-1 684 ±  86** 108.9 + 12.9**
♦Patellae {n = 6) were incubated for 48 h in RPMI supplemented with 0.25 ng/ml KiF-l. 
The concentrations of IL-la and LIF were 10 ng/ml and 100 ng/ml. respectively, 
fMedium was changed after 24 li (200 (.il/patella). NO was measured in pooled "samples of 
both 24-h incubation periods using Griess reagents and NOa as a standard.
^Proteoglycan synthesis (mean value ±  SD) as measured by ["Sjsullatc incorporation in the 
last 3 h of' the 4S-!i incubation period. Control group and cytokine treated group were tested 
using the Student’s Most, values statistically significant: **P < 0.05.
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TABLE 5. Role of nitric oxide in IL-1-, and LIF-induced inhibition of proteoglycan synthesis.
Patellar cartilage expiants* Femoral head cartilage*
Culture
[■15S]sulfateJ Nitrite§ [MS]sulfate Nitrite
incorporation concentration incorporation concentration
Mice mediumt (cpm ± SD) (HM) (cpm ± SD) aovo
C57Bl/6xl29Sv (IL-6+ + ) 1703 ±  173 25.2 ±6 .1 8872 ± 1237 13.2 ±2 .3
NMMA 1723 ±  157 7.8 ±  1.5** 8682 + 1513 7.2 ±  1.6**
IL-l 684 ±  86 108.6 ±  12.9 3827 ±  784 53.8 ±  13.0
IL-l +  NM M A 1016 ±  74** 8.9 ±  3.1** 6328 ±  1106** 8.0 ±  2.2**
L IF 1288 ±  115 25.9 ±  4.2 6305 ±1791 20.4 ±  2.0
L IF  + NMMA 1460 +  108** 8.3 ± 1.7** 5860 ±  1215 10.7 ±  1.7**
C57Bl/6xl29Sv (IL-6'’'") --- 1777 ±  194 23.1 + 6.5 8212 ±  1070 16.7 ±  1.9
NM MA 1569 ±  231 8.9 ± 1.5** 7614 ±  1345 7.7 ±  2.0**
IL-l 558 ±  126M IM 119.1 ± 18.3 4812 ±  899 60.4 ±  9.4
IL-l +  NMMA 1153 ±  168** 9.3 ±  2.9** 6585 ±  648** 8.9 ±  3.0**
L IF 1364 -t 186 31.5 ±  5.3 6865 ±  1185 20.4 ±  2.9
LIF +  NM M A 1060 ±155** 10.7 ±  2.6** 6240 ±1017 10.7 ±  1.7**
*Femoral head cartilage explants (n «= 6) and patellae (n «  6) were incubated in RPMI supplemented with 0.25 jig/ml IGF-1, 1 specimen per 
200 |d medium. Medium was changed after 24 h, and the total incubation period was 48 h.
fThe IL-lot concentrations were IQng/ml and 0,1 ng/ml in patellae and femoral head explants, respectively. The NMMA concentration used 
was 1 mg/ml. The LIF concentrations were 100 ng/ml and 25 ng/ml in patellae and femoral head explants, respectively.
{Proteoglycan synthesis (mean value ±  SD) as measured by P*S]sulfate (20 |iCi/ml) uptake during the last 3 h of incubation.
§NO was measured in pooled samples of both 24-h incubation periods using Griess reagents and NOi as a standard.
NMMA-treated groups and their respective control groups were tested using the Wilcoxon rank sum test, values were statistically significant: 
**p<  0.05. Note that the NMMA treatment had opposite effect on IL-l and LIF-indueed proteoglycan synthesis suppression.
L-arginine (NM M A). A concentration of 1 mg/ml of 
NM M A completely prevented the IL-l-inducible 
NO production and significantly reduced the IL-l 
effect on proteoglycan synthesis in cultures of patellae 
and femoral head cartilage obtained from IL-6 *1
or I L-6°/0 mice (Table 5). Incubation of femoral 
head cartilage explants or patellae with LIF did 
not increase the NO-levels in their conditioned 
medium. In the presence of N M M A , as expected, LIF- 
induced suppression of proteoglycan synthesis was not 
decreased (Table 5).
Role o f  endogenous IL-6 in the suppression o f  
proteoglycan synthesis studied in vivo using 
normal and IL-6ol° mice
we ex'
in vivo. A si
the role of IL-6 in the 
of chondrocyte proteoglycan synthesis
of 10 ng murine IL -la
given intra-articularly in the right knee provoked a 
pronounced suppression of proteoglycan synthesis 
of —47.5 ±  10.0% in IL-60/0 mice (mean of four 
experiments) (Table 6). This was not significantly 
different from the IL-l induced suppression in IL-6+/ + 
mice: —42.5 ±  15.1%, IL-6 seems not to be essential. 
However, high dosages of IL-l were needed to provoke 
a clear suppression of the chondrocyte proteoglycan 
synthesis,14 therefore, to meet more physiological levels 
of IL-l, heat-inactivated zymosan was injected into the 
joint cavity. This elicited local cytokine production 
with IL-l peak values at the 3rd hour, and IL-6 peak 
values at the 6th hour after zymosan injection (Fig. 2). 
At 48 h after zymosan injection, IL-l and IL-6 
levels returned to baseline (Fig. 2). At all time points 
taken, wash-out of patellae with adjacent synovial 
tissue demonstrated increased amounts of NO during 
arthritis (Fig. 2). The amounts of IL-l and NO found
TABLE 6. 1L— 1 — or arthritis-induced inhibition of proteoglycan synthesis in patellae.
( ’57BI/6 (IL-fi ♦ / I ) C57BI/6xl29Sv (tL-6l,iu)
- V » .  . . . . . . . . . . . . . . . . . . . . . . . . . . . .  t.‘f .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ate incorporation* 
(com ± Í
[■'\S]sul fa te i neo rporation
(cpm ± SD)
< 1 ^ <  <^111 i f . . — H ,  I V
M ice *I une Left Right Suppression Left Right Suppression
IL-l injectionf Exp 1. Day 1 1722 + 263 1018 +  203 41 % 1406 +  232¥ tlMUl 814 ±  131 42%
Exp 1. Day 2 1880 +  304 714 +  164 62% 1838 +  488 749 +  119 59%
Zy ni osa n- i nd ueed a rt h r i t i sif Exp 2. Day 2 2456 ±  382 1202 +  121 51 % 2264 +  382 872 +  63OBNM, 61 %
Exp 3. Day 2 3957 + 712 1483 + 205 63% 4153 +  891, i^ i  m 1137 + 198r t n n 73%
* Patellae of right and left knee joints (// -  6 mice per group) were dissected and ex vivo labeled with [uS]s ul fate for 3 h.
L-la (King) was injected intra-articularly into the right knee joint.
{Monoarticular arthritis was elicited by intra-articular injection of lK0j.ig of heat-inactivated zymosan into the right knee joint. No differences in joint swelling 
(^technetium uptake) between the two mouse strains were found at day two of arthritis (data not shown).
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Figure 2. IL-1, IL-6, and NO release by patellae with adjacent 
synovial tissue during the course of zymosan-induced arthritis.
Patellae with adjacent soft tissue were dissected in a standardized 
manner to obtain large specimen of synovia. Patellae were incubated 
in 200 |il RPMI for 1 h at room temperature followed by 24 h at 3 7 ’C 
for assessment of IL-1/IL-6 (A,B) and NO (C), respectively. Data 
represent the mean value of 4 patellae per time point, IL-l and NO 
levels between IL-61' 1 and IL-6"'" mice were not significantly 
different. IL-6 in conditioned media of patellae from IL*6‘''” mice 
could not be detected using the B9 assay. ND = not done.
during zymosan-induced arthritis were not 
cantly different between IL-6oA’ mice and their normal 
littermates (Fig. 2). Furthermore, arthritis caused a 
marked suppression of proteoglycan synthesis in both 
mouse strains (Table 6). This demonstrated that IL-6 
was not a necessary (co)factor in the IL-1 i 
arthritis related suppression of chondrocyte 
glycan synthesis in vivo.
DISCUSSION
The cytokines IL-1 and LIF are both 
o f suppressing chondrocyte proteoglycan synthesis in
neutralizing anti-m uri ne articular cartilage.
bodies and knock-out mice, we demonstrated that
IL-6 did not ate the IL-1 and LIF o n
in
chondrocyte synthesis. Furthermore, both cytokines 
have independent second mediator pathways involved 
in the suppression of proteoglycan synthesis, IL-1 was 
partly mediated by NO and LIF was not mediated by
NO.
Little is known about the local role of IL-6 i 
cartilage pathology of arthritis. There is circumstantial 
evidence that IL-6 plays a costimulatory role in the 
IL-1-induced suppression of proteoglycan
articular cartilage expiants.21,22 However, 
if in these studies IL-1 dosages of 40 pg/ml or higher
of IL-6 neutralization on the
IL-1-induced proteoglycan synthesis suppression was 
found. The lowest IL-1 dose we used in this study
m
were n o
was 100 pg/ml, 
synovial
was in the normal range of 
in rheumatoid arthritis,*7IL-1
Furthermore, we demonstrated that during murine 
experimental arthritis (ZIA) sufficient amounts 
IL-1 were synthesized in the joint to 
suppression of proteoglycan synthesis.14 Induction of 
arthritis in IL-6-deficient mice also resulted in local 
IL-1 generation, and in a pronounced inhibition, 
indistinguishable of that seen in IL-6 * ' + mice. For this, 
IL-6 was not involved in the IL-1 induced suppression 
of chondrocyte proteoglycan synthesis in murine 
articular cartilage. This was in line with a previous 
in vivo study in which we observed that anti-IL-6 
antibody treatment had no o n t h e
proteoglycan synthesis during antigen-induced arthritis
although in that particular we could not
exclude that the endogenous IL-6 was not completely
of IL-6 was unable to modulate the effect of low and 
high dosages of IL-1 on 
synthesis in mouse (Table 3), and in other sp ec ie s .w 
We and others found that bovine chondrocytes did not
;e IL-6 spontaneously or after IL-1
IL-1 m a r
o u r ua
amounts of
int IL-6 also had no effect on normal 
or IL-l affected proteoglycan synthesis in the bovine
vations in 
human recoin
system (data not shown). argues against an
essential role for IL-6 in the IL-1-induced suppression
o f
articular cartilage. I
in this case, in bovine
•>«> we can not exc a
possible bypass in bovine chondrocytes because of
of IL-6 synthesis in response to IL-1 
have occurred in the IL-6-defieientand this could 
mice. For '  í 01 IL-6 neutrali;
experiments using anti-IL-6 antibodies in cultures of 
isolated murine articular chondrocytes and on cartilage
IL-l-i
al ¡zing IL-6 bioacti did not prevent
syn
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thesis, confirming the results obtained in the IL-6-
m ic e .
LIF, a mediator downstream in the 
cascade in RA, could also inhibit chondrocyte proteo­
glycan synthesis in murine articular cartilage. In order 
to investigate whether IL-6 mediated the LIF effect, 
LIF was tested on cartilage of IL-60/l> mice. Since 
similar suppression of proteoglycan synthesis was 
found, IL-6 seems not to be essential. LIF belongs to 
a group of related cytokines including IL-6, which have 
overlapping functions and share the same signal-tran- 
ducing peptide (gpl30) in conjunction their
non-signalling cytokine-specific receptors.41-43 However, 
IL-6 could not suppr
in mouse (Table 3), cow,40 and 3K.W
showed that LIF and IL-6 differential
43.44
activities as was already seen in other cell systems, e.g. 
macrophage differentiation and several bioassays.
If these cytokines are not always interchangeable, 
IL-6 may antagonize LIF by competing for the gpI30 
receptor. High levels of L IF  (ranging from 1 to 
43 ng/ml) were found in synovial fluid of patients with 
rheumatoid arthritis (RA).45 The amounts o f  LIF used 
in the present study were, however, higher (10 and 
100 ng/ml). On the other hand, in cultures of patellae 
the concentration of IL-6 reached values between 
150 and 300 ng/ml, which was also at least 15 times
higher than the concentrations found in synovial
fluid of RA-patients, 10-25 ng/ml. 34,46,47 r nFor is, the
concentrations of IL-6 in conditioned media matched 
the am ounts of LIF used in this study. The
inhibitors of the NO-synthase prevent the LIF effect on 
human cartilage.
The N M M A  treatment reduced NO-levels below 
the background values, still a significant suppression 
of proteoglycan synthesis was evident using IL-1, 
suggesting that inhibition by IL-1 was not fully 
NO-dependent in murine articular cartilage. Further­
more, LIF inhibited proteoglycan synthesis indepen­
dent of NO, suggesting that there are at least two 
distinct, independent intracellular pathways which 
lead to proteoglycan synthesis suppression. It must be 
noticed that the proteoglycan synthesis in porcine and 
caprine cartilage20 was considerably more suppressed 
by LIF than in murine cartilage (Table 4). It is possible 
that also LIF operates via different pathways in the 
various species.
observations were obtained in 
the bovine system. The inhibitor of iNOS, NMMA 
had no effect on human recombinant IL-1 (3-induced 
suppression of proteoglycan synthesis in 
articular cartilage explants.50 However, we (data not 
published) and another group51 could completely block 
the IL-1-induced proteoglycan synthesis suppression 
with the addition of NMMA in primary 
of bovine chondrocytes, suggesting that culture 
conditions may determine which pathway is taken.
Experimental arthritis in mouse caused a sharp 
increase of IL-1, IL-6 and NO levels in wash-outs of 
patellae with adjacent synovial tissue obtained within 
the first 24 h after onset. NO-production was not 
impaired in cartilage isolated from IL-6"/0 mice, as was
of LIF on proteoglycan synthesis was not enhanced in 
cartilage derived from IL-60/0 mice as compared to
IL-6 mice, arguing against the premise of compe­
tition between IL-6 and LIF  for the gpl30 receptor 
in chondrocytes.
Recently, several groups observed that the 
IL-1-induced suppression o f 
was mediated by autocrine NO in rabbit,21’ rat, 
human chondrocytes.48 LIF suppressed proteoglycan 
synthesis in porcine and caprine cartilage.2 
NO is also involved in the action of LIF has yet to
30 .
be . In this study we
role of NO in the IL-1- and LIF-induced inhibition
isis. Murine chondrocytes spon-of proteoglycan s
taneously released NO during culture and IL-1, but 
not LIF, increased NO synthesis. In contrast, human
already
i n .il
for peritoneal macro 
Therefore, it is highly unlikely that 
IL-6 was involved in IL-1 and NO synthesis during 
arthritis. Preliminary data of the cartilage destruction 
in zymosan-induced arthritis, a non-immunologically 
mediated inflammation,52 revealed an enhanced proteo-
slvcan loss in IL-6-deficient mice as to
normal ( 1L -61 ' ' ) mice. Experiments are in
to examine role IL-6 in the process of
destruction during imental arthi
i-IL -l/TN F treatment may reduce IL-6 
ial fluid of RA-patients and one may
m
replenish 1 L-6 for its beneficial effects on cartilage.
T
■ h w of IL-6 are in synovial
o l amed joints in rheumatoid arthritis and
:t, e.g. on acute phase proteins
recombinant IL-1 and LIP’
NO-syn in
were capable of 
human articular
and lever, the local effects on cartilage remain to be
. We demonstrated that both IL-1 and LIF
chondrocytes.48,41' Besides the 
ence, isolated chondrocytes may well react differently 
on LIF as compared to chondrocytes maintained in 
their extracellular matrix. Blocking NO-synthesis using 
the NO antagonist, N M M A , significantly alleviated the
on •e
IL-6 independent, in vitro and in vivo. Furthermore, 
we confirmed the mediating role of NO in IL-l-i 
suppression, but clearly showed that 
NO independent. This argues against the existence of
IL-1- but not LIF-induced
suppression in mice, and it remains to be seen whether
a IL-1 -+ LIF IL-6 -> NO ease
o f
m 1L-I-
in
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murine ar ar cart ila «e. Our data s u g g e s t h a t
IL-6 is not a feasible downstream target to fine tune
IL-l-directed therapy, to prevent cartilage damage. 
Furthermore, the strategy of NO blocking in RA will 
a fleet IL-1 action, but probably not that of LIF.
and no bioactive IL-6 was found in conditioned medium of 
cartilage cultures from IL-61’1’ mice.
Cartilage explant culture
Patellae were dissected with a minimal of surrounding 
soft tissue (ligament, muscle and synovium), and femoral
M ATERIALS AND M ETH O D S
head expiants were obtained by 
layer from
the cartilage
Anim als
Homozygous IL-6"" and wild-type (C57Bl/6x 129/Sv)F2 
mice were obtained from M. Kopf (Germany) and bred 
in our own animal facilities, as were the C57BI/6 mice. 
Mice were housed in filler top cages under standard pathogen
a standard diet and tapwater
femur by a firm twist
mts were incubated in 200 jaI RPMl-1640 
modification) medium with Glutamax-1 (Gibco BRL, Life 
Technologies, Scotland, UK) supplemented with 0.25 gg/rnl 
human recombinant insulin-like growth factor (IGF)-l, and 
amicin (50 mg/1) at 37"C in a humidified 5%
atmosphere.
free conditions and 
ad lihitum. At the age of 8 10 weeks they were used in the
experiments.
Recombinant cytokines and antibodies
Purified and biologically active mature murine re­
combinant IL-la, cloned in Escherichia coli, was generously 
donated by I.G. Otterness (Pfizer Central Research, Groton 
CT, USA) and bioactivity was checked in a bioassay. 
Purified murine recombinant IL-6 was a gift from G.
(I.R.B.M., Rome Italy), and murine 
nant LIF (carrier free) was purchased from R&D Systems 
Ltd (Europe). Rat anti-mouse IL-6 monoclonal antibody 
(IgGl) was purchased by Genzyme Corp (Cambridge MA, 
USA). Neutralizing capacity was verified in the IL-6 
bioassay.
Chondrocyte isolation, c e and proteoglycan
Femoral head cartilage t \  L }
overnight with 120 IJ eollagenase ( Clostridium
in a
in
lyticunu Worthington, IJK) in 2 ml of RPMl-1640 culture 
medium supplemented with 2% BSA. Chondrocytes were 
centrifugated at 250 x g for 10 min and resuspended in 
RPM1 1640 + 5% fetal calf serum. Viability was checked 
by trypan-blue exclusion and cell-number was determined. 
Around 5 x 10'1 chondrocytes were plated per 
flat-bottom 96-wetl plate and incubated in 200 jliI medium. 
After 24 h, 50-pi samples per well were taken for IL-6 
determination, thereafter, 1 |.iCi of [-'sS]sulfate/50 j-tl medium 
was added to each well and incubation was continued for
;r 4 h. Incubation was terminated by storing the plate 
at —20 C. After thawing, medium was vigorously pipetted a 
times to disrupt the cells and the [''S]sulfale~labelled 
proteoglycans were precipitated with cetylpyridinium ehlor- 
as previously described before.'4
Assessment o f proteoglycan synthesis in cartilage
Control of IL-6-deficiency
The IL-6 gene was 
by insertion of a neo cassette.'1’'" Loss of wild-type IL-6 
messenger RNA was confirmed by reverse transcriptase 
(RT)-PCR using primers bridging the insertion: 5', TCT
GCA AGA GAC TTC CAT CCA; 3', GCA AGT GCA TCA
TTC," purchased from Pharmacia Biotech 
(Roosedaal, The Netherlands). Controls were included for a 
possible bypass of IL-6 by IL-11. Sequences of the primers 
for IL-11 were upstream (5') (5')CTG TGG GGA CAT GAA 
CTG TG(3') and downstream (3') (5')AGC CTT GTC AGC 
ACA CCA G(3'). Messenger RNA from cartilage or syno- Groningen, The Netherlands). The "S-content of each patella 
vial tissue, isolated with TRIzol reagent according to the was measured by liquid scintillation counting and expressed 
protocol of the manufacturer (Life Technology, Breda, The as counts per minute (cpm). Data are represented as total
Cartilage specimens (patellae or femoral heads) were 
placed in RPMl 1640 supplemented with 
(50 mg/1), L-glutamine (2 mM) and 40 |,iCi | '\S (sulfate. At the 
end of the 3-h incubation period, patellae were lixed in 10% 
formalin and subsequently decalcified in formic acid (5%),
and dissolved in 0.5 ml Lumasolve (Luinac,
Netherlands), was reverse-transcribed to complementary incorporation of ["SJsulfate or as a ratio of right over left
knee (within animal control value) as paired values.
Assessment o f  cytokine bioactivities
IL-1 activity was measured in the one-stage proliferation
DNA (cDNA) using oligi-dT primers by standard protocol. 
One twentieth of the cDNA was used for one PCR reaction 
of 35 cycles; denaturing at 92"C for 1 min, annealing at 55' C 
for 1 min, followed by elongation with Taq
at 72' C for 1 min. The expected PCR 
products of IL-6 and IL-11 were 239 and 300 base pairs, 
respectively. This control was performed regularly during 
breeding of the animals. In cartilage obtained from IL-6"" 
mice, no IL-6 mRNA was detected, whereas IL-6 mRNA was 
present in cartilage from IL-6+/l mice, and marked 
enhancement was found after IL-1 challenge. There was
in cartilage
assay as ;d by Gearing et «/." The murine thymoma 
cell line EL-4 NOB-1 (ECACC, Porton Down, Salisbury,
Wilts, UK) was as an IL-1 specific cell producing
IL-2 in response, in combination with the IL-2 sensitive
CTLL2-cells (ECACC). s were plated out in
concentrations of 1 x 10’/well NOB I-cells and 4 x I O'/well
n o of enhanced IL-1I
from IL-60/" mice. Second, culture supernatant of articular 
cartilage was cheeked for IL-6 bioactive using the B9~assay,
CTLL-eells in RPMI supplemented with 5% letal calf serum
(FCS) for 21 h.
IL-6 activity was determined by a proliferative assay
cells. Briefly, 5 x 10' -cells in 200 t^l 5%
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FCS-RPMI 1640 per well were plated in a round-bottom 
microtitre plate and incubated for 3 days using human 
recombinant IL-6 as standards.
At the end of the incubation (both IL-1 and IL-6 assay).
0.5 i-tCi of [■1H]thymidine activity 20 Ci/mmol,
Dupont, NEN products, Boston, MA) was added per well.
were harvested and thymidineThree hours later, 
incorporation (NOB1 cell are thymidine kinase deficient) 
was determined. Detection limit of the IL-1 assay was 
0.1 pg/ml murine recombinant IL-1 and for the IL-6 assay 
was 1 pg/ml.
Nitrite determination
The medium concentration of NCK (a stable break-V
down product of NO) was determined by Griess reaction 
using N aN 02 standards. Griess reagent; 0.1% naphthyl- 
ethylene diamine dihydrochloride, 1:1 diluted with 1.0% 
sulfanilamide in 5% HiPO*. Briefly, 100 Ltl of conditioned
medium was with 100f.il of Griess in a
flat-bottom microtitre plate and adsorbance read at 545 nm 
using an ELISA plate reader.
Zymosan -induced arthritis
A homogeneous suspension of 30 mg zymosan A 
(Saccharomyces cennnsiae), dissolved in 1 ml endotoxin-free 
saline, was obtained by boiling twice, and sonic émulsifica­
tion. Arthritis was induced by intra-articular injection of 
180 |ig zymosan along the suprapatellar ligament into the 
joint cavity. The contralateral knee joint received an equal 
amount of saline (6 (.tl) and served as a within animal control. 
At day 2 of arthritis, joint swelling was measured, there­
after, patellae were isolated to assess cytokine levels and
Assessment o f  joint swelling
Animals were subeutaneously with 10|iCi 
‘'Technetium pertechnetate (wTc) in 0.2 ml saline in the neck 
region. After 15 min, mice were sedated by intraperitoneal 
injection of 4.5% chloral hydrate, 0.1 ml/10 mg of body 
weight. The accumulation of the isotope due to the increased 
blood flow and edema in the knee was determined by external 
gamma counting and expressed as the ratio of the *wTc uptake 
in inflamed over contralateral knee joint. A ratio higher than 
1.1 indicates joint swelling.
Assessment o f  cytokine production by arthritic joints
Patellae were dissected with surrounding soft-lissue 
consisting out of the tendon, and synovium in a standardized 
manner. Kach patella was incubated in 200 pi serum free 
RPMI 1640 after 1 h at 37"C temperature, culture medium
was sampled and stored at — 70 C proceeding cytokine 
measurements, patellae were provided with new medium and 
incubated lor another 24 h, thereafter, medium was stored at 
20 C proceeding nitrite measurements.
Statistical analysis
Data are expressed as mean values ± standard deviation 
unless staled otherwise. Statistical significance was
using Wilcoxon’s rank sum test or with
Student’s /-test as stated in the legends.
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